Login to Your Account

Turnaround Continues

Valeant Sells European Ops to Meda for $392M in Cash

By Trista Morrison

Tuesday, August 5, 2008
As part of an ongoing effort to streamline and focus its operations, Valeant Pharmaceuticals International sold its Western and Eastern European businesses to specialty pharma company Meda AB for $392 million in cash. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription